Anat Shirvan
Keine laufenden Positionen mehr
Profil
Anat Shirvan is the founder of Aposense Ltd., which was founded in 1996.
She held the title of Director & EVP-Research & Development from 2011 to 2014.
Dr. Shirvan also worked as Vice President-Research & Development at Atox Bio Ltd.
from 2010 to 2015.
She earned a doctorate degree from The Hebrew University of Jerusalem.
Ehemalige bekannte Positionen von Anat Shirvan
| Unternehmen | Position | Ende |
|---|---|---|
Atox Bio Ltd.
 Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Technik-/Wissenschafts-/F&E-Leiter | - |
| APOSENSE LTD | Gründer | - |
Ausbildung von Anat Shirvan
| The Hebrew University of Jerusalem | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Aposense Ltd.
 Aposense Ltd. Pharmaceuticals: MajorHealth Technology Aposense Ltd. engages in the provision of proprietary conjugates. It offers platform technology which comprises the rational design of small molecular moieties with the increased affinity to the cell membranes imparting the conjugates compound with improved drug properties such as extended life span oral bioavailabity and selective at target site. The company was founded by Ilan Ziv and Jacob Gottenstein on October 9, 1996 and is headquartered in Petach-Tikva, Israel. | Health Technology |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Health Technology |